Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Exactly! Here is another one for you. The Exon 20 insertion mutation trial recently added HER2 mutations in addition to EGFR mutations. The ongoing Korean mBC trial (not the one to be presented at ESMO) revised the protocol in Nov 2016 to add EGFR mutations in addition to HER2 mutations. The US mBC trial is for HER2 patients, w the protocol last updated in Oct 2016. So what are the odds that they'll will modify the protocol to include EGFR mutations? Just something to ponder.